Viruses, Vol. 14, Pages 1246: Comparison of qPCR with ddPCR for the Quantification of JC Polyomavirus in CSF from Patients with Progressive Multifocal Leukoencephalopathy
Conclusion: This study shows strong correlation between ddPCR and qPCR with increased sensitivity of the ddPCR assay. Further work will be needed to determine whether multiplex ddPCR can be useful to determine PML risk in natalizumab-treated MS patients. (Source: Viruses)
Source: Viruses - June 8, 2022 Category: Virology Authors: Nyater Ngouth Maria Chiara Monaco Lorenzo Walker Sydney Corey Ijeoma Ikpeama Gary Fahle Irene Cortese Sanchita Das Steven Jacobson Tags: Article Source Type: research
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis
Natalizumab and fingolimod are used as high-efficacy treatments in relapsing –remitting multiple sclerosis. Several observational studies comparing these two drugs have shown variable results, using different m... (Source: BMC Medical Research Methodology)
Source: BMC Medical Research Methodology - May 30, 2022 Category: Research Authors: M. Lefort, S. Sharmin, J. B. Andersen, S. Vukusic, R. Casey, M. Debouverie, G. Edan, J. Ciron, A. Ruet, J. De S èze, E. Maillart, H. Zephir, P. Labauge, G. Defer, C. Lebrun-Frenay, T. Moreau & hellip; Tags: Research Source Type: research
006 Secondary amenorrhea related to natalizumab
Conclusion
Whereas a simple temporal association between a drug use and a particular event does not necessarily indicate a direct causal relationship, the occurrence of amenorrhoea in our patient linked to the start of Natalizumab and its resolution 3 months post treatment cessation, is too good of a coincidence to be fully dismissed.
leonora.fisniku@nhs.net (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - May 27, 2022 Category: Neurosurgery Authors: Obeng, L., Brown, H., Wheately, T., Good, C., Fisniku, L. Tags: Poster Presentations Source Type: research
011 UK variance in DMT advice and prescribing in MS and pregnancy
Conclusions
There remains significant variation in advice given to women with MS considering pregnancy. This is most marked with higher efficacy DMT, where risk-benefit decision making is complex. Additional data and resources for women with MS, including a UK MS Pregnancy register, are urgently needed.
ruth.dobson@qmul.ac.uk (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - May 27, 2022 Category: Neurosurgery Authors: Dobson, R., Hughes, S., Ford, H., Murray, K., Pearson, O., Brex, P., Rog, D. Tags: Poster Presentations Source Type: research
014 Long-term effectiveness of natalizumab for RRMS: UK and global interim results from TYSABRI observational program
Conclusions
These TOP UK results show disease control that is generally consistent with global TOP results, supporting natalizumab’s long-term effectiveness in real-world settings.
Support
Biogen. Disclosures: Included on the poster.
richard.nicholas@btinternet.com (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - May 27, 2022 Category: Neurosurgery Authors: Nicholas, R., Harrower, T., Su, R., Licata, S., Vonsy, J. Tags: Poster Presentations Source Type: research
018 Disease control beyond NEDA: the value of non-clinical measures to determine treatment response to natalizumab
Conclusion
MRI activity, sNfL, and relapses had the strongest natalizumab treatment association over 2 years in AFFIRM. sNfL may be useful in defining disease control with natalizumab.
*Additional authors: Richard A. Rudick (Biogen, Cambridge, MA, USA), Al Sandrock (Biogen, Cambridge, MA, USA). Support: Biogen. Disclosures: Included on poster.
g.giovannoni@qmul.ac.uk (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - May 27, 2022 Category: Neurosurgery Authors: Calabresi, P. A., Kappos, L., Giovannoni, G., Plavina, T., Koulinska, I., Edwards, M. R., Kieseier, B., Moor, C. d., Fisher, E. Tags: Poster Presentations Source Type: research
021 Determinants of natalizumab-associated PML outcomes
Conclusions
PLEX had no significant effect on survival rates. Numerically worse 2-year survival probabilities were observed with PLEX regardless of PML presentation, suggesting PLEX is not effective for improving post-PML outcomes.
Support
Biogen. Disclosures: Included on the poster.
g.giovannoni@qmul.ac.uk (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - May 27, 2022 Category: Neurosurgery Authors: Kappos, L., McGuigan, C., Derfuss, T., Giovannoni, G., Oh, J., Ren, Z., McCarthy, K., Chang, I., Campbell, N. Tags: Poster Presentations Source Type: research
023 Relapse outcomes with natalizumab Q4W vs switch to Q6W
Conclusions
No significant difference in relapse outcomes was observed between patients who switched
4t6o Q6W and those who remained on Q4W. An ongoing randomized prospective trial of Q4W vs Q6W will inform further on the effectiveness of natalizumab Q6W. Support: Biogen.
peiran.ho@biogen.com (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - May 27, 2022 Category: Neurosurgery Authors: Butzkueven, H., Kappos, L., Spelman, T., Trojano, M., Wiendl, H., Su, R., Hyde, R., Licata, S., Ho, P.-R., Campbell, N. Tags: Poster Presentations Source Type: research
027 Eosinophilia and lymphocytosis after natalizumab for relapsing-remitting multiple sclerosis
Conclusion
Eosinophilia and lymphocytosis are common, and have clinical and service implications, affecting medical management and monitoring frequency. Data presented will inform practice.
milad_kazava@yahoo.co.uk (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - May 27, 2022 Category: Neurosurgery Authors: Keshvari, M.-K., Sheikh, S., Someren, F. v., Galea, I. Tags: Poster Presentations Source Type: research
040 MS disease modifying therapy (DMT) sequencing - natalizumab to cladribine tablets - experience in 20 patients
Conclusion
According to this review of 20 patients, treatment with cladribine tablets was safe even when used in patients previously treated with natalizumab and at high risk for PML. So far, no serious adverse events other than transient lymphopenia have been observed, especially no cases of PML.
j.das@doctors.org.uk (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - May 27, 2022 Category: Neurosurgery Authors: Das, J., Lewis, T., Lusher, W., Vernon, K., Rog, D., Paul, T., Sharaf, N., Kalatha, T., Mihalova, T. Tags: Poster Presentations Source Type: research
219 MRI monitoring in MS patients prescribed disease monitoring treatments in Kings College Hospital
To date the MRI monitoring of MS patients on disease modifying treatments at KCH has gone unquanti- fied. This audit aimed to quantify and evaluate our current use of MRI in monitoring treatment response and safety in patients prescribed disease modifying treatments(DMTS)
A list of patients prescribed DMTs between April 2016 and July 2019 was obtained via the Blueteq system. We used Cogstack to extract all MRI scan reports available for these patients (excluding pre-treatment scans). Every scan report was reviewed manually and the presence of new or enlarging T2 lesions and contrast enhancing lesions were documented for ea...
Source: Journal of Neurology, Neurosurgery and Psychiatry - May 27, 2022 Category: Neurosurgery Authors: Raftopoulos, R., Teo, J., Jarosz, J., Brex, P. Tags: Poster Presentations Source Type: research
088 Brainstem progressive multifocal leukoencephalopathy
Progressive multifocal leukoencephalopathy (PML) is a rare but potentially fatal viral brain infection seen in immunocompromised patients and in patients with multiple sclerosis (MS) on disease-modifying treatments such as natalizumab. The most frequent reported pattern of PML is that of large subcortical T2 and diffusion hyperintense lesions. Brainstem PML, although previously reported, is rare and therefore easily missed.
A 46-year-old lady with a diagnosis of MS on treatment with natalizumab for 5 years, serum JC virus high positive; presented with worsening of long-standing unsteadiness. Prior imaging showed multiple s...
Source: Journal of Neurology, Neurosurgery and Psychiatry - May 27, 2022 Category: Neurosurgery Authors: Hawken, J., Pearson, O., Smith, R., Sadiq, S., Ingram, G. Tags: Live Poster, 13 May Poster Session 3 Source Type: research
104 A case of natalizumab-related progressive multifocal leukoencephalopathy treated with pembrolizumab
Discussion
This case highlights the difficulty in distinguishing PML from an MS relapse, despite the use of MRI and CSF. We highlight the role of brain biopsy in making a definitive diagnosis. There is also lack of consensus on effective treatment for PML, but emerging evidence for use of pembrolizumab, a PD-1 inhibitor.
rrobinson17@qub.ac.uk
77 (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - May 27, 2022 Category: Neurosurgery Authors: Robinson, R., Ramsay, S., Burns, P., Flynn, P., Herron, B., Poots, J., Kennedy, F., Hughes, S. Tags: Live Poster, 13 May Poster Session 3 Source Type: research
108 UK multiple sclerosis service and DMT audit of 70 centres: variation in DMT prescribing
Conclusions
DMT prescribing variations are expected, but important, if associated with differing outcomes. We recommend the substantial DMT spend and its increase, demands UK investment to: maximise processes (full data reporting to prescribers) and outcome measurement (including dashboard of longi- tudinal and peer-benchmark prescribing practice, eg induction vs escalation approaches and sequenc- ing) to provide optimal real world evidence to guide prescribing.
Acknowledgements
Neurology Academy david.rog@srft.nhs.uk
79 (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - May 27, 2022 Category: Neurosurgery Authors: Rog, D., Mathews, J., Hobart, J., Raising the Bar 4 MS UK MS Study Group Tags: Live Poster, 13 May Poster Session 3 Source Type: research
119 Long-term effectiveness of natalizumab for RRMS: UK and global interim results from TYSABRI observational program
Conclusions
The reduction in ARR on natalizumab was similar in the TOP UK and global cohorts, including in the subset of patients with one prior DMT. These findings support the real-world effectiveness of natalizumab.
Support.Biogen. Disclosures: Included on the poster. jean.vonsy@biogen.com (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - May 27, 2022 Category: Neurosurgery Authors: Nicholas, R., Harrower, T., Liao, S., Vonsy, J. Tags: Live Poster, 29 April SIG1: MS [amp ] Neuroinflammation Source Type: research
